IMV is a user of Twitter and maintains a corporate account using the screen names @imv_inc.
IMV recognizes the importance of social media, including Twitter, and new communication channels that enable IMV to engage in interactive discussion with the Company’s stakeholders. As a clinical-stage drug development company, IMV is committed to abiding by the legal, ethical and regulatory standards applicable to the Company. By maintaining an active Twitter account, IMV aims to responsibly interact with stakeholders.
IMV may respond to questions and comments that are presented via Twitter when appropriate. IMV may not be able to respond immediately to questions or comments, and responses, if any, may be limited in nature.
There may be questions and/or comments that IMV cannot address, including, but not limited to, questions that are related to non-public confidential information, proprietary information, financial matters, ongoing legal matters, regulatory issues and other aspects of IMV’s business. IMV will not respond to rumors, personal attacks, foul language, disparaging comments or topics that do not relate directly to IMV.
Twitter accounts that IMV follows or is followed by do not indicate an endorsement of the account owner or their products and services.
IMV may provide links or references to external websites that are not controlled by IMV as part of its Tweets. However, IMV does not endorse or claim responsibility for the content of such websites. Any links or references to such external websites are provided merely as a convenience to the users of the Twitter platform.
IMV reserves all rights that relate to the IMV Twitter account @imv_inc, including, but not limited to, all rights to add, remove or modify any content or material that is posted on the account; discontinue the account; accept or reject those who may wish to follow the account; and respond to, or refrain from responding to, any questions or comments that are addressed to the account.